“Pfizer (PFE) Beat The Numbers And People Just Yawned,” Says Jim Cramer

We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the ...

How Pfizer Stock Can Rebound

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer: Market Still Pricing It At Crisis Valuations

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Pfizer (PFE): Is There Untapped Value in Today’s Evolving Pharmaceutical Market?

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...
Blockonomi

Pfizer (PFE) Stock: Pharma Giant Battles Novo Nordisk Over $9 Billion Metsera Deal

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer: The Storm Has Passed -- Tailwinds Ahead

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Should You Buy Pfizer Stock Before Nov. 4?

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and ...